News for SELLAS Life Sciences Group, Inc. (SLS)

On May 22, 2025, Katherine Kalin, a Director at SELLAS Life Sciences Group Inc (SLS), purchased 20,000 shares of the company. Following this transaction, the in

SELLAS Life Sciences (SLS) has made progress in its Phase 2 trial targeting pediatric acute myeloid leukemia (AML) by administering the first dose to a young pa

SELLAS Life Sciences (SLS) achieves milestone by dosing first pediatric patient in Phase 2 trial for SLS009 in relapsed/refractory AML. The trial is sup

**media[627053]**

Key Highlights: SELLAS Life Sciences (SLS) exceeds earnings expectations with a quarterly GAAP EPS of -$0.07. Analysts predict significant upside potenti

”“ Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (

Sellas Life Sciences (SLS) has reported encouraging developments in its ongoing research initiatives. The company's CEO, Angelos Stergiou, highlighted that thei

Preclinical data shows a 97% reduction in TP53-mutated leukemia cells with SLS009 when combined with standard therapy. Phase 2 trials reveal a median ov

New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells NEW YORK, Apri

SELLAS Life Sciences Group (NASDAQ: SLS) to present preclinical efficacy data of SLS009 at ASCO 2025. The presentation will focus on ASXL1 mutated colorecta

**media[603414]**

Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia.

**media[589210]**

”“ Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Fin

Get insights into SELLAS Life Sciences' FY earnings. GAAP EPS outperforms estimates by $0.04.

**media[572457]**

PR NewswireVANCOUVER, BC, Feb. 27, 2025 USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US

**media[545781]**

**media[526616]**